Meditation

This passage speaks of two realities that seem to exclude each other: the Holy Spirit and critical testing. We ask: Is it not of the very essence of the Holy Spirit that, where He is at work, critical testing ceases? And again: Must not critical testing, if it is to be fruitful, exclude all prophetic inspirations

Alternative forest management strategies to account for climate change-induced productivity and species suitability changes in Europe

We present for the first time a study on alternative forest management at the European scale to account for climate change impacts. We combine insights into detailed studies at high resolution with the actual status of the forest and a realistic estimate of the current management practices at large scale. Results show that the European forest system is very inert and that it takes a long time to influence the species distribution by replacing species after final felling. By 2070, on average about 36 % of the area expected to have decreased species suitability will have changed species following business as usual management. Alternative management, consisting of shorter rotations for those species and species planting based on expected trends, will have increased this species transition to 40 %. The simulated forward-looking alternative management leads to some reduction in increment, but does not influence the amount of wood removed from the forest. Northern Europe is projected to show the highest production increases under climate change and can also adapt faster to the new (proposed) species distribution. Southwest Europe is expected to face the greatest challenge by a combination of a predicted loss of production and a slow rate of management alteration under climate change

The 3q Oncogene SEC62 Predicts Response to Neoadjuvant Chemotherapy and Regulates Tumor Cell Migration in Triple Negative Breast Cancer

In the absence of targeted treatment options, neoadjuvant chemotherapy (NACT) is applied widely for triple-negative breast cancer (TNBC). Response to NACT is an important parameter predictive of oncological outcomes (progression-free and overall survival). An approach to the evaluation of predictive markers enabling therapy individualization is the identification of tumor driver genetic mutations. This study was conducted to investigate the role of SEC62, harbored at 3q26 and identified as a driver of breast cancer pathogenesis, in TNBC. We analyzed SEC62 expression in The Cancer Genome Atlas database, and immunohistologically investigated SEC62 expression in pre- and post-NACT tissue samples from 64 patients with TNBC treated at the Department of Gynecology and Obstetrics/Saarland University Hospital/Homburg between January 2010 and December 2018 and compared the effect of SEC62 on tumor cell migration and proliferation in functional assays. SEC62 expression dynamics correlated positively with the response to NACT (p ≤ 0.01) and oncological outcomes (p ≤ 0.01). SEC62 expression stimulated tumor cell migration (p ≤ 0.01). The study findings indicate that SEC62 is overexpressed in TNBC and serves as a predictive marker for the response to NACT, a prognostic marker for oncological outcomes, and a migration-stimulating oncogene in TNBC